Company intelligence / Profile preview

Fortress Biotech

Bay Harbor Islands, Florida, USAen.wikipedia.org ↗

Ownership: Public · FBIO
Development stage: Commercial

Overview

Fortress Biotech is advancing several clinical programs, including a PDUFA goal date for CUTX-101 and commercial launches like Emrosi for rosacea. It has a diverse pipeline across multiple therapeutic areas.

Therapeutic areas: OncologyRare DiseasesDermatology
Modalities: Includes small molecules and biologics, though specific modalities are not detailed.
Industry: Biotech

Drug pipeline

8 assets

methazolamide

Approved

7 more assets in the full pipeline.

Request access →

Partnerships

AstraZenecaCity of HopeFred Hutchinson Cancer CenterNationwide Children’s HospitalSentynl

Financials

Market cap: $85.4M
Total revenue: $18.7M
Enterprise value: $-46.4M

Beyond the preview

Go deeper on Fortress Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fortress Biotech.

Explore the full profile